- Home
- RHI vs LEGN Comparison
RHI vs LEGN Comparison
Compare RHI & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RHI
- LEGN
- Stock Information
- Founded
- RHI 1948
- LEGN 2014
- Country
- RHI United States
- LEGN United States
- Employees
- RHI N/A
- LEGN N/A
- Industry
- RHI Professional Services
- LEGN Biotechnology: Pharmaceutical Preparations
- Sector
- RHI Consumer Discretionary
- LEGN Health Care
- Exchange
- RHI Nasdaq
- LEGN Nasdaq
- Market Cap
- RHI 6.1B
- LEGN 7.0B
- IPO Year
- RHI N/A
- LEGN 2020
- Fundamental
- Price
- RHI $54.54
- LEGN $33.93
- Analyst Decision
- RHI Hold
- LEGN Strong Buy
- Analyst Count
- RHI 6
- LEGN 12
- Target Price
- RHI $69.00
- LEGN $79.00
- AVG Volume (30 Days)
- RHI 1.7M
- LEGN 1.1M
- Earning Date
- RHI 04-24-2025
- LEGN 03-11-2025
- Dividend Yield
- RHI 4.33%
- LEGN N/A
- EPS Growth
- RHI N/A
- LEGN N/A
- EPS
- RHI 2.44
- LEGN N/A
- Revenue
- RHI $5,795,837,000.00
- LEGN $627,241,000.00
- Revenue This Year
- RHI $2.59
- LEGN $66.76
- Revenue Next Year
- RHI $8.26
- LEGN $51.82
- P/E Ratio
- RHI $22.35
- LEGN N/A
- Revenue Growth
- RHI N/A
- LEGN 119.97
- 52 Week Low
- RHI $51.55
- LEGN $30.17
- 52 Week High
- RHI $79.27
- LEGN $60.87
- Technical
- Relative Strength Index (RSI)
- RHI 44.30
- LEGN 39.62
- Support Level
- RHI $53.13
- LEGN $34.00
- Resistance Level
- RHI $55.14
- LEGN $36.20
- Average True Range (ATR)
- RHI 1.31
- LEGN 1.39
- MACD
- RHI 0.46
- LEGN -0.33
- Stochastic Oscillator
- RHI 82.14
- LEGN 18.23
About RHI Robert Half Inc.
Robert Half Inc was founded in 1948, Robert Half provides temporary, permanent, and outcome-based staffing for both in-person and remote positions in the finance and accounting, technology, legal, marketing, and administrative fields. Its subsidiary consulting arm, Protiviti, specializes in technology, risk, auditing, and compliance matters. The firm generates its sales inside the U.S. and is one of the specialized firms in the fragmented U.S. staffing industry. The firm generates annual revenue of around $7 billion.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.